Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Novartis AGNYSE: NVS

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit declines year over year

Q2 FY2026 gross profit of $10.74B fell 6.7% year over year, behind the -1.6% change in trailing-twelve-month gross profit. Sequentially, it rose 6.7% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.

Context

  • Gross profit amounted to 75.0% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.7% toward the trailing-twelve-month pace of -1.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$10.74B+6.7% QoQ
Last fiscal yearDec 2025
$41.12B+5.7% YoY
LTMJun 2026
$41.41B-1.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.7%——
1 year+5.7%——
3-year CAGR+8.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
41.12B USD
Year-over-year change
+5.7%
4-year CAGR
+6.3%

Gross Profit vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.6% is the lowest of 11, against a peer median of +5.5%.
  • Gross profit amounts to 74.4% of revenue for NVS, versus a peer median of 74.3%.
NVS Competitors
Gross Profit for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 265.68B DKK+1.5%+19.0%80.6%
JNJJohnson & JohnsonLTM Sep 2026$68.35B USD+9.0%+4.9%68.8%
ABBVAbbVie Inc.LTM Sep 2026$50.34B USD+21.0%+1.9%76.3%
MRKMerck & Co., Inc.LTM Jun 2026$50.05B USD+4.1%+3.7%75.4%
AZNAstraZeneca PLCLTM Sep 2026$49.79B USD+4.0%+14.6%80.1%
PFEPfizer Inc.LTM Jun 2026$46.61B USD+1.2%-11.4%73.2%
NVSNovartis AGLTM Jun 2026$41.41B USD-1.6%+8.9%74.4%
SNYSanofiLTM Jun 2026€35.72B EUR+15.6%+5.5%73.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$34.51B USD+2.9%-1.7%70.2%
GILDGilead Sciences, Inc.LTM Jun 2026$24.24B USD+6.9%+2.4%79.6%
GSKGSK plcLTM Jun 2026£24.15B GBP+7.0%+6.2%72.7%
Peer median (excluding NVS) —+5.5%+4.3%74.3%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.97B43.46B46.66B51.72B54.81B
Cost of Revenue11.74B11.58B12.47B12.83B13.69B
Gross Profit32.24B31.88B34.19B38.9B41.12B
Gross Margin73.3%73.4%73.3%75.2%75.0%
Research & Development8.64B9.17B11.37B10.02B10.74B
Selling, General & Admin12.83B12.19B12.52B12.57B13.31B
Operating Expenses22.18B23.93B24.42B24.35B24.05B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
EBITDA30.91B14.68B18.26B20.72B22.99B
EBITDA Margin70.3%33.8%39.1%40.1%41.9%
Operating Income10.06B7.95B9.77B14.54B17.07B
Operating Margin22.9%18.3%20.9%28.1%31.2%
Interest Income71M377.74M629.24M567.68M374.91M
Interest Expense905M834.62M876.12M1.04B1.19B
Other Income / Expenses14.47B(769M)(646M)(904M)(638.25M)
Income Before Tax24.53B7.18B9.12B13.64B16.44B
Pre-Tax Margin55.8%16.5%19.6%26.4%30.0%
Income Tax Expense1.63B1.13B551M1.7B2.4B
Net Income24.02B6.96B14.85B11.94B14.06B
Net Margin54.6%16.0%31.8%23.1%25.6%
EPS (Basic)10.713.197.155.927.25
EPS (Diluted)10.633.177.105.877.19
Weighted Avg Shares2.24B2.18B2.08B2.02B1.94B
Weighted Avg Shares (Diluted)2.26B2.2B2.09B2.04B1.96B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.